Due to a limited supply, we are unable to accept phone calls to schedule COVID-19 vaccinations.
For the most up-to-date information, please check our COVID-19 Vaccination Website.
Marc C. Smaldone, MD, MSHP, FACS
- Request Appointment
- Clinical Locations
- About
- Education and Training
- Patient Stories
- Research Profile
- Publications
- Ratings
Clinical Locations
Primary Location
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Secondary Location
Fox Chase Cancer Center Huntingdon Pike
8 Huntingdon Pike
Rockledge, PA 19046
About
Associate Professor, Department of Surgical Oncology
NCCN, Prostate Cancer Early Detection Panel Member
Specialties
Treatment Focus
- Robotic and laparoscopic minimally invasive surgery
- Continent urinary diversion
- Salvage and reconstructive Surgery
Research Program
Treatment Philosophy
I am a urologic oncologist specializing in the surgical management of tumors of the kidney, bladder, prostate, adrenal, testis and other genitourinary organs. As part of the multi-disciplinary Genitourinary Cancer Patient Care Team, I work closely with my colleagues in Medical and Radiation Oncology to develop a comprehensive treatment plan that offers the best chance for cure for each patient.
The mission at the Fox Chase Cancer Center is to deliver world class oncologic care in the most compassionate and respectful way possible. A cancer diagnosis brings fear and uncertainty for patients and their families, and my personal philosophy is to treat patients how I would wish for my family members to be treated. Patient education is essential, and I consider it of utmost importance to take the time necessary for patients to understand and feel comfortable with all possible treatment options to inspire confident decision making.
I have expertise in open, laparoscopic, and robotic surgical techniques, which allows me to tailor a specific treatment plan based on individual patient need and preferences. I have particular expertise in minimally invasive organ preserving and reconstructive techniques to preserve function and quality of life, including nerve-sparing prostatectomy for patients with prostate cancer and partial nephrectomy for patients with kidney cancer. I have experience performing both robotic and open cystectomy for patients with bladder cancer, and prefer to construct continent urinary diversions whenever possible. I have a clinical interest in the surgical management of patients with high risk and advanced disease, and have experience performing retroperitoneal lymph node dissection following chemotherapy in patients with testicular cancer, cytoreductive nephrectomy and thrombectomy for patients with metastatic kidney cancer or tumors extending into the vena cava, and salvage surgery following radiation for patients with bladder or prostate cancer.
Follow on Twitter: @FCUroOnc
Education and Training
Educational Background
- Fellowship: Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA
- Residency: Urologic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA
- MS, Health Policy Research, University of Pennsylvania, Philadelphia, PA
- MD, State University of New York at Stony Brook School of Medicine, Stony Brook, NY
Certifications
- American Board of Urology
Memberships
- National Comprehensive Cancer Network (NCCN)
- Prostate Cancer Early Detection Panel
- American Urological Association
- Society of Urologic Oncology
Honors & Awards
- Main Line Today Top Doctors, 2018-2019
Patient Stories
Bill Doyle
Bladder Cancer
Bill Doyle
Bladder Cancer
Bill Doyle always knew he wanted to be on the radio. As one half of the Deminski & Doyle talk radio show on New Jersey 101.5, life was good for Bill until he was diagnosed with bladder cancer at 52. After surgery and several rounds of chemotherapy, Bill is back on the airwaves, thanks in part to the support of his family and the countless 101.5 listeners who have offered words of support during his cancer journey.
John Mullarkey, Jr.
Prostate Cancer
John Mullarkey, Jr.
Prostate Cancer
I have always been proactive about my health and started having annual prostate exams when I turned 50 in 2007. My first report was great and showed that my PSA level was undetectable.
Sister Marcille McEntee
Skin Cancer; Ureteral Cancer
Sister Marcille McEntee
Skin Cancer; Ureteral Cancer
Her gastroenterologist performed a PET scan which revealed a rare kind of cancer, a mucosal melanoma. “At that point, my urologist admitted 'this is beyond me. You need to go somewhere else',” she recalled.
Chuck Leonard
Kidney Cancer
Chuck Leonard
Kidney Cancer
In August 2012, at the age of 61, Chuck Leonard was diagnosed with stage four kidney cancer that had metastasized to his lungs. After seeing one doctor, Chuck decided to seek a second opinion from a specialist at Fox Chase Cancer Center, where he planned to take part in a clinical trial. However, additional testing revealed he was a candidate for surgery. Chuck also underwent radiation using Cyberknife technology at Fox Chase Buckingham after an MRI revealed the kidney cancer had spread to his brain. “In 2016, I can mark three years since I have had detectable cancer,” he said. “I’m so thankful for all the outstanding care, both medical and other, provided by Fox Chase and the caring doctors and nurses. Hopefully, my tests will continue to have good outcomes, and, if not, I know I’m getting the best care possible from Fox Chase Cancer Center.”
Michael Laurenzi
Kidney Cancer; Pancreatic Cancer
Michael Laurenzi
Kidney Cancer; Pancreatic Cancer
'I am very lucky the tick bit me, because I had no symptoms and no idea that I had cancer. I have nothing but the highest regard for those doctors and their teams. They are so caring and compassionate, and they literally gave me my life back.'
Pages
Research Profile
Research Program
Research Interests
- Quality of care
- Comparative effectiveness
- Risk assessment
- Access disparities
- Surgical outcomes
- Health services research
Publications
Selected Publications
Correa AF, Handorf E, Joshi SS, Geynisman DM, Kutikov A, Chen DY, Uzzo RG, Viterbo R, Greenberg RE, Smaldone MC. Differences in Survival Associated with Performance of Lymph Node Dissection in Patients with Invasive Penile Cancer: Results from the National Cancer Database. J Urol, 199(5):1238-44, 2018. PubMed
Goel N, Manstein SM, Ward WH, DeMora L, Smaldone MC, Farma JM, Uzzo RG, Esnaola NF. Does the Surgical Apgar Score predict serious complications after elective major cancer surgery? Journal of Surgical Research, 231:242-7, 2018.
Smaldone, M.C., Corcoran, A.T., Hayn M.H., Konety, B.R., Hrebinko Jr., R.L., Davies, B.J. (2009). Estimation of mortality and morbidity risk in patients undergoing radical cystectomy with continent diversion using the POSSUM and Portsmouth POSSUM predictor equations. J Urol,182(6): 2619-24. PubMed
Smaldone, M.C., Cowan, J., Carroll, P.R., Davies, B.J. (2010). Comparison of eligibility for active surveillance and pathologic outcomes in men undergoing radical prostatectomy in a large community-based cohort. J Urol,183(1):138-43. PubMed
Kutikov, A., Smaldone, M.C., Egleston, B.L., Manley, B.J., Simhan, J., Boorjian, S.A., Viterbo, R., Chen, D.Y., Greenberg, R.E., Uzzo, R.G. (2011). Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephromety Score. Eur Urol, 60(2): 241-8. PubMed
Smaldone, M.C., Kutikov, A., Egleston, B., Simhan, J., Canter, D.J., Teper, E., Viterbo, R., Chen, D.Y., Greenberg, R.E., Uzzo, R.G. (2012). Assessing performance trends in laparoscopic nephrectomy and nephron sparing surgery for localized renal tumors. Urology, 80(2): 286-92. PubMed
Smaldone, M.C., Kutikov, A., Egleston, B.L., Canter, D.J., Viterbo, R., Chen, D.Y., Jewett, M.A., Greenberg, R.E., Uzzo, R.G. (2012). Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer, 118(4):997-1006. PubMed
Smaldone, M.C., Egleston, B.L., Uzzo, R.G., Kutikov, A. (2012). Does partial nephrectomy result in a durable overall survival benefit in the Medicare population? J Urol 188(6): 2089-94. PubMed
Kutikov, A., Egleston, B.L., Canter, D., Smaldone, M.C., Wong, Y.N., Uzzo, R.G. (2012). Competing risks of death in patients with localized renal cell carcinoma: a comorbidity based model. J Urol, 188(6): 2077-83. PubMed
Smaldone, M.C., Simhan, J., Kutikov, A., Canter, D.J., Starkey, R., Zhu, F., Nielsen, M.E., Stitzenberg, K.B., Greenberg, R.E., Uzzo, R.G. (2013) Trends in regionalization of radical cystectomy in three large northeastern states from 1996 to 2009. Urol Oncol, 31(8): 1663-9. PubMed
Tomaszewski, J.J., Uzzo, R.G., Handorf, E.A., Bekelman, J.E., Corcoran, A.T., Kutikov, A., Mehrazin, R., Smaldone, M.C. (2014) Care transitions between hospitals are associated with treatment delays for patients with muscle invasive bladder cancer. J Urol, 192(5): 1349-54. PubMed
Kim, S.P, Gross, C.P., Nguyen, P.L., Smaldone, M.C., Shah, N.D., Karnes, R.J., Thompson, R.H., Hand, L.C., Yu, J.B., Trinh, Q.D., Ziegenfuss, J.Y., Sun, M., Tilburt, J.C. (2014) Perceptions of active surveillance and treatment recommendations for low-risk prostate cancer: Results from a national survey of radiation oncologists and urologists. Med Care, 52(7):579-85. PubMed
Martin, J.M., Handorf, E.A., Kutikov, A., Uzzo, R.G., Bekelman, J.E., Horwitz, E.M., Smaldone, M.C. (2014) The rise and fall of prostate brachytherapy: Use of brachytherapy in the treatment of localized prostate cancer in the National Cancer Database. Cancer, 120(14):2114-21. PubMed
Corcoran, A.T., Handorf, E, Canter, D, Tomaszewski, J.J., Bekelman, J.E., Kim, S.P., Uzzo, R.G., Kutikov. A, Smaldone, M.C. (2015) Variation in performance of candidate surgical quality measures for muscle invasive bladder cancer by hospital type. BJU Int, 115(2):230-7. PubMed
Wang, E.H., Gross, C.P., Tilburt, J.C., Yu, J.B., Nguyen, P.L., Smaldone, M.C., Shah, N.D., Abouassally, R., Sun, M., Kim, S.P. Shared decision making and use of decision AIDS for localized prostate cancer: perceptions from radiation oncologists and urologists. (2015) JAMA Intern Med, 175(5):792-9. PubMed
Additional Publications
Clinical Locations
Primary Location
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Secondary Location
Fox Chase Cancer Center Huntingdon Pike
8 Huntingdon Pike
Rockledge, PA 19046
Associate Professor, Department of Surgical Oncology
NCCN, Prostate Cancer Early Detection Panel Member
Treatment Focus
- Robotic and laparoscopic minimally invasive surgery
- Continent urinary diversion
- Salvage and reconstructive Surgery
Research Program
Treatment Philosophy
I am a urologic oncologist specializing in the surgical management of tumors of the kidney, bladder, prostate, adrenal, testis and other genitourinary organs. As part of the multi-disciplinary Genitourinary Cancer Patient Care Team, I work closely with my colleagues in Medical and Radiation Oncology to develop a comprehensive treatment plan that offers the best chance for cure for each patient.
The mission at the Fox Chase Cancer Center is to deliver world class oncologic care in the most compassionate and respectful way possible. A cancer diagnosis brings fear and uncertainty for patients and their families, and my personal philosophy is to treat patients how I would wish for my family members to be treated. Patient education is essential, and I consider it of utmost importance to take the time necessary for patients to understand and feel comfortable with all possible treatment options to inspire confident decision making.
I have expertise in open, laparoscopic, and robotic surgical techniques, which allows me to tailor a specific treatment plan based on individual patient need and preferences. I have particular expertise in minimally invasive organ preserving and reconstructive techniques to preserve function and quality of life, including nerve-sparing prostatectomy for patients with prostate cancer and partial nephrectomy for patients with kidney cancer. I have experience performing both robotic and open cystectomy for patients with bladder cancer, and prefer to construct continent urinary diversions whenever possible. I have a clinical interest in the surgical management of patients with high risk and advanced disease, and have experience performing retroperitoneal lymph node dissection following chemotherapy in patients with testicular cancer, cytoreductive nephrectomy and thrombectomy for patients with metastatic kidney cancer or tumors extending into the vena cava, and salvage surgery following radiation for patients with bladder or prostate cancer.
Follow on Twitter: @FCUroOnc
Education
Educational Background
- Fellowship: Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA
- Residency: Urologic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA
- MS, Health Policy Research, University of Pennsylvania, Philadelphia, PA
- MD, State University of New York at Stony Brook School of Medicine, Stony Brook, NY
Certifications
- American Board of Urology
Memberships
- National Comprehensive Cancer Network (NCCN)
- Prostate Cancer Early Detection Panel
- American Urological Association
- Society of Urologic Oncology
Honors & Awards
- Main Line Today Top Doctors, 2018-2019
Research Profile
Research Interests
- Quality of care
- Comparative effectiveness
- Risk assessment
- Access disparities
- Surgical outcomes
- Health services research
Publications
Selected Publications
Correa AF, Handorf E, Joshi SS, Geynisman DM, Kutikov A, Chen DY, Uzzo RG, Viterbo R, Greenberg RE, Smaldone MC. Differences in Survival Associated with Performance of Lymph Node Dissection in Patients with Invasive Penile Cancer: Results from the National Cancer Database. J Urol, 199(5):1238-44, 2018. PubMed
Goel N, Manstein SM, Ward WH, DeMora L, Smaldone MC, Farma JM, Uzzo RG, Esnaola NF. Does the Surgical Apgar Score predict serious complications after elective major cancer surgery? Journal of Surgical Research, 231:242-7, 2018.
Smaldone, M.C., Corcoran, A.T., Hayn M.H., Konety, B.R., Hrebinko Jr., R.L., Davies, B.J. (2009). Estimation of mortality and morbidity risk in patients undergoing radical cystectomy with continent diversion using the POSSUM and Portsmouth POSSUM predictor equations. J Urol,182(6): 2619-24. PubMed
Smaldone, M.C., Cowan, J., Carroll, P.R., Davies, B.J. (2010). Comparison of eligibility for active surveillance and pathologic outcomes in men undergoing radical prostatectomy in a large community-based cohort. J Urol,183(1):138-43. PubMed
Kutikov, A., Smaldone, M.C., Egleston, B.L., Manley, B.J., Simhan, J., Boorjian, S.A., Viterbo, R., Chen, D.Y., Greenberg, R.E., Uzzo, R.G. (2011). Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephromety Score. Eur Urol, 60(2): 241-8. PubMed
Smaldone, M.C., Kutikov, A., Egleston, B., Simhan, J., Canter, D.J., Teper, E., Viterbo, R., Chen, D.Y., Greenberg, R.E., Uzzo, R.G. (2012). Assessing performance trends in laparoscopic nephrectomy and nephron sparing surgery for localized renal tumors. Urology, 80(2): 286-92. PubMed
Smaldone, M.C., Kutikov, A., Egleston, B.L., Canter, D.J., Viterbo, R., Chen, D.Y., Jewett, M.A., Greenberg, R.E., Uzzo, R.G. (2012). Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer, 118(4):997-1006. PubMed
Smaldone, M.C., Egleston, B.L., Uzzo, R.G., Kutikov, A. (2012). Does partial nephrectomy result in a durable overall survival benefit in the Medicare population? J Urol 188(6): 2089-94. PubMed
Kutikov, A., Egleston, B.L., Canter, D., Smaldone, M.C., Wong, Y.N., Uzzo, R.G. (2012). Competing risks of death in patients with localized renal cell carcinoma: a comorbidity based model. J Urol, 188(6): 2077-83. PubMed
Smaldone, M.C., Simhan, J., Kutikov, A., Canter, D.J., Starkey, R., Zhu, F., Nielsen, M.E., Stitzenberg, K.B., Greenberg, R.E., Uzzo, R.G. (2013) Trends in regionalization of radical cystectomy in three large northeastern states from 1996 to 2009. Urol Oncol, 31(8): 1663-9. PubMed
Tomaszewski, J.J., Uzzo, R.G., Handorf, E.A., Bekelman, J.E., Corcoran, A.T., Kutikov, A., Mehrazin, R., Smaldone, M.C. (2014) Care transitions between hospitals are associated with treatment delays for patients with muscle invasive bladder cancer. J Urol, 192(5): 1349-54. PubMed
Kim, S.P, Gross, C.P., Nguyen, P.L., Smaldone, M.C., Shah, N.D., Karnes, R.J., Thompson, R.H., Hand, L.C., Yu, J.B., Trinh, Q.D., Ziegenfuss, J.Y., Sun, M., Tilburt, J.C. (2014) Perceptions of active surveillance and treatment recommendations for low-risk prostate cancer: Results from a national survey of radiation oncologists and urologists. Med Care, 52(7):579-85. PubMed
Martin, J.M., Handorf, E.A., Kutikov, A., Uzzo, R.G., Bekelman, J.E., Horwitz, E.M., Smaldone, M.C. (2014) The rise and fall of prostate brachytherapy: Use of brachytherapy in the treatment of localized prostate cancer in the National Cancer Database. Cancer, 120(14):2114-21. PubMed
Corcoran, A.T., Handorf, E, Canter, D, Tomaszewski, J.J., Bekelman, J.E., Kim, S.P., Uzzo, R.G., Kutikov. A, Smaldone, M.C. (2015) Variation in performance of candidate surgical quality measures for muscle invasive bladder cancer by hospital type. BJU Int, 115(2):230-7. PubMed
Wang, E.H., Gross, C.P., Tilburt, J.C., Yu, J.B., Nguyen, P.L., Smaldone, M.C., Shah, N.D., Abouassally, R., Sun, M., Kim, S.P. Shared decision making and use of decision AIDS for localized prostate cancer: perceptions from radiation oncologists and urologists. (2015) JAMA Intern Med, 175(5):792-9. PubMed
Additional Publications
Related Articles
98 PATIENT COMMENTS
-
5.0
December 29, 2020
Fox Chase staff and Dr. Smaldone are the best their is - so thankful to have such a caring kind and truly gifted doctor.
-
5.0
December 28, 2020
I love Fox Chase Hospital, and all what everyone has done for me much thanks to Marc Smaldone, MD, and staff.
-
5.0
December 26, 2020
great dr. and nurses and fantastic office personnel
-
No Star Ratings Available
December 26, 2020
Dr. Smaldone is excellent with his physical abilities as well as his bedside manner and doctor patient dialogue.
-
5.0
December 22, 2020
I have always received excellent care from Dr Smaldone and his staff.
-
5.0
December 21, 2020
Always a good experience.
-
5.0
December 18, 2020
every thing was good including my results. [...]
-
No Star Ratings Available
December 18, 2020
most accessible and friendly physician I have ever had
-
5.0
December 15, 2020
Received great care from Dr. Smaldone.
-
5.0
December 02, 2020
Best doctor and staff that I go to!!!
-
5.0
November 28, 2020
best doctor/specialist I have ever had.
-
No Star Ratings Available
November 28, 2020
I have told everyone I know about my fantastic experiences with Dr Smaldone and Fox Chase
-
5.0
November 25, 2020
Dr. Marc Smaldone and his staff are excellent. I would highly recommend him.
-
No Star Ratings Available
November 24, 2020
ggood
-
No Star Ratings Available
November 22, 2020
Dr. Smaldone has consistently and faithfully ordered the testing against which results may be compared and contrasted with those accomplished since my treatment. aahe has informed me of even the slightest deviations in results and whether or not action may be advised. He pays strict attention to even the slightest details, which means a great deal to me in that it is indicative of his sterling professional caliber as well as a measure of the quality of his personal character. I had only bad experiences BEFORE I met him and have thanked God for bringing Dr. Smaldone into my life, which, I am more than convinced was saved and has been preserved by him.
-
5.0
November 13, 2020
Dr Smaldone is the best. Listens to you and provides clear and concise feedback. He makes you feel comfortable. Always a positive experience dealing with him and his group.
-
No Star Ratings Available
November 07, 2020
Great doctor! Came in early to discuss things with me, took the time and care to call my family immediately with any and all updates & is very quick to respond to any and all questions or concerns I may have.
-
No Star Ratings Available
October 21, 2020
good
-
5.0
September 22, 2020
Doctor Marc and the entire staff including the hospital staff took excellent care of me.
-
5.0
September 04, 2020
Very pleased with Dr. Smaldone and staff.So grateful to have my care at Fox Chase Cancer Center.
LOAD MORE